138 related articles for article (PubMed ID: 22803642)
1. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.
Scott G; Ahmad I; Howard K; MacLean D; Oliva C; Warrington S; Wilbraham D; Worthington P
Br J Clin Pharmacol; 2013 Feb; 75(2):381-91. PubMed ID: 22803642
[TBL] [Abstract][Full Text] [Related]
2. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
MacLean DB; Matsui H; Suri A; Neuwirth R; Colombel M
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1445-53. PubMed ID: 24762108
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
[TBL] [Abstract][Full Text] [Related]
4. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
MacLean DB; Shi H; Faessel HM; Saad F
J Clin Endocrinol Metab; 2015 Dec; 100(12):4579-87. PubMed ID: 26502357
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects.
Fedyk ER; Zhao L; Koch A; Smithson G; Estevam J; Chen G; Lahu G; Roepcke S; Lin J; Mclean L
Br J Clin Pharmacol; 2020 Jul; 86(7):1314-1325. PubMed ID: 32045493
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Jenkins H; Sakurai Y; Nishimura A; Okamoto H; Hibberd M; Jenkins R; Yoneyama T; Ashida K; Ogama Y; Warrington S
Aliment Pharmacol Ther; 2015 Apr; 41(7):636-48. PubMed ID: 25707624
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.
Matsui H; Tanaka A; Yokoyama K; Takatsu Y; Ishikawa K; Asami T; Nishizawa N; Suzuki A; Kumano S; Terada M; Kusaka M; Kitada C; Ohtaki T
Endocrinology; 2012 Nov; 153(11):5297-308. PubMed ID: 23027808
[TBL] [Abstract][Full Text] [Related]
8. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model.
Tanaka A; Nakata D; Masaki T; Kusaka M; Watanabe T; Matsui H
Eur J Pharmacol; 2018 Mar; 822():138-146. PubMed ID: 29355559
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model.
Kogame A; Ishikawa K; DeJongh J; Tagawa Y; Matsui H; Moriya Y; Kondo T; Asahi S
Biopharm Drug Dispos; 2020 Jul; 41(7):283-294. PubMed ID: 32562504
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
[TBL] [Abstract][Full Text] [Related]
13. The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S; Benet LZ
Drug Metab Dispos; 2019 Sep; 47(9):1004-1012. PubMed ID: 31201213
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation.
Brearley C; Jaber A; Bertolino M; Priestley A; Seiberling M
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):307-18. PubMed ID: 17595888
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study.
Li X; Sun F; Zhang X; Lin P; Shen K; Shen Y; Ma L; Cao Y; Wang C
BMC Med; 2023 Apr; 21(1):129. PubMed ID: 37013610
[TBL] [Abstract][Full Text] [Related]
16. Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.
Thirumalai A; Ceponis J; Amory JK; Swerdloff R; Surampudi V; Liu PY; Bremner WJ; Harvey E; Blithe DL; Lee MS; Hull L; Wang C; Page ST
J Clin Endocrinol Metab; 2019 Feb; 104(2):423-432. PubMed ID: 30252061
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.
Sakurai Y; Nishimura A; Kennedy G; Hibberd M; Jenkins R; Okamoto H; Yoneyama T; Jenkins H; Ashida K; Irie S; Täubel J
Clin Transl Gastroenterol; 2015 Jun; 6(6):e94. PubMed ID: 26111126
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.
Ishikawa K; Tanaka A; Kogame A; Watanabe T; Tagawa Y; Matsui H
Eur J Pharmacol; 2018 Jun; 828():126-134. PubMed ID: 29580912
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A.
Yin W; Arkilo D; Khudyakov P; Hazel J; Gupta S; Quinton MS; Lin J; Hartman DS; Bednar MM; Rosen L; Wendland JR
Br J Clin Pharmacol; 2021 Dec; 87(12):4756-4768. PubMed ID: 33990969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
